1. Home
  2. TAYD vs BDTX Comparison

TAYD vs BDTX Comparison

Compare TAYD & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Taylor Devices Inc.

TAYD

Taylor Devices Inc.

HOLD

Current Price

$53.60

Market Cap

170.7M

Sector

Industrials

ML Signal

HOLD

Logo Black Diamond Therapeutics Inc.

BDTX

Black Diamond Therapeutics Inc.

HOLD

Current Price

$1.79

Market Cap

171.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TAYD
BDTX
Founded
1955
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
170.7M
171.9M
IPO Year
1995
2020

Fundamental Metrics

Financial Performance
Metric
TAYD
BDTX
Price
$53.60
$1.79
Analyst Decision
Hold
Strong Buy
Analyst Count
1
7
Target Price
$70.00
$9.67
AVG Volume (30 Days)
47.3K
1.6M
Earning Date
03-31-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
11.24
130.71
EPS
2.87
N/A
Revenue
$46,292,725.00
N/A
Revenue This Year
$0.25
N/A
Revenue Next Year
$19.78
N/A
P/E Ratio
$18.63
N/A
Revenue Growth
3.84
N/A
52 Week Low
$40.50
$1.60
52 Week High
$90.37
$4.94

Technical Indicators

Market Signals
Indicator
TAYD
BDTX
Relative Strength Index (RSI) 43.01 42.31
Support Level $53.46 $1.76
Resistance Level $61.21 $2.26
Average True Range (ATR) 2.53 0.11
MACD -0.39 0.01
Stochastic Oscillator 11.66 6.17

Price Performance

Historical Comparison
TAYD
BDTX

About TAYD Taylor Devices Inc.

Taylor Devices Inc is involved in the design, development, manufacture, and marketing of shock absorption, rate control, and energy storage devices for use in various types of machinery, equipment, and structures. The company's product line includes Seismic dampers, Fluidicshoks, Crane and industrial buffers, Self-adjusting shock absorbers, Liquid die springs, and Vibration Dampers. Its products are generally used to absorb, control, or mitigate the motion of masses caused by earthquakes or explosions. The company markets its products to various industries such as industrial, steel mills, buildings, bridges, aerospace, defense, and automotive industries.

About BDTX Black Diamond Therapeutics Inc.

Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.

Share on Social Networks: